Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)
NCT00304629Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2000
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 3, open-label, single-arm trial of galantamine in Alzheimer's disease (AD), sponsored by Johnson & Johnson. Primary endpoint: Safety. Started Mar 2000; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00304629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304629.